이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma (LuDO-N)

2026년 11월 3일 업데이트: Jakob Stenman

A Phase II Trial of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma

The LuDO-N Trial is a multi-centre phase II clinical trial on 177Lu-DOTATATE treatment of recurrent or relapsed high-risk neuroblastoma in children. The LuDO-N Trial builds on the experience from the previous LuDO Trial and utilises an intensified dosing schedule to deliver 2 doses over a 2-week period, in order to achieve a maximal effect on the often rapidly progressing disease. This strategy requires a readiness for autologous stem cell transplantation in all patients, but is not anticipated to increase the risk of long-term sequelae, since the cumulative radiation dose remains unchanged. The primary aim of the study is to assess the response to 177Lu-DOTATATE treatment at 1 and 4 months after end of treatment. Secondary aims are to assess survival and treatment-related toxicity. Additional aim are to correlate tumour dosimetry with response, correlate SSTR-2 expression with 68Ga-DOTATATE uptake and to correlate the uptake with the treatment response.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

24

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Utrecht
      • Utrecht, Utrecht, 네덜란드, NL-3584
        • 모병
        • Princess Maxima Center for Pediatric Oncology
        • 연락하다:
        • 수석 연구원:
          • Max M van Noesel, MD PhD
    • Oslo
      • Oslo, Oslo, 노르웨이, NO-0372
        • 모병
        • Oslo University Hospital, Rikshospitalet
        • 연락하다:
        • 수석 연구원:
          • Kirsten Brunsvig Jarvis, MD
    • Copenhagen
      • Copenhagen, Copenhagen, 덴마크, DK-2100
        • 모병
        • Rigshospitalet
        • 연락하다:
        • 수석 연구원:
          • Jesper S Brok, MD PhD
    • Vilnius County
      • Vilnius, Vilnius County, 리투아니아, LT-08406
        • 모병
        • Vilnius University Hospital
        • 연락하다:
        • 수석 연구원:
          • Jelena Rascon, MD PhD
      • Barcelona, 스페인
        • 모병
        • Pediatric Cancer Center Barcelona, Sant Joan de Déu Barcelona Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Maite Gorostegui Obanos, MD
      • Glasgow, 영국, G51 4TF
        • 모병
        • GREATER GLASGOW HEALTH BOARD, Royal Hospital for Children
        • 연락하다:
        • 수석 연구원:
          • Diana Mcintosh, MD
      • London, 영국, NW1 2PG
        • 모병
        • University College London Hospitals NHS FOUNDATION TRUST
        • 연락하다:
          • Jenny Gains, Consultant in Clinical Oncolog
          • 전화번호: +44-203 447 4437
          • 이메일: jenny.gains@nhs.net
        • 수석 연구원:
          • Jenny Gains, MD
      • London, 영국, SW3 6JJ
        • 모병
        • The Royal Marsden NHS Foundation Trust of Fulham Road
        • 연락하다:
        • 수석 연구원:
          • Sucheta Vaidya, MD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

1년 이상 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Pathology 1.1. Histologically confirmed diagnosis of neuroblastoma 1.2. Immunohistochemical staining for somatostatin receptors (SSTR) performed from primary tumor tissue when available
  2. Relapsed or primary refractory high-risk neuroblastoma: INSS stage 4 disease or INRGSS stage M disease
  3. Age >18 months at the time of enrolment into this study
  4. Life expectancy of greater than 3 months
  5. Performance Status 5.1. Karnofsky > 50% (for patients > 12 years of age) 5.2. Lansky > 50% (for patients ≤ 12 years of age)
  6. Prior treatment 6.1. Two-week washout from any prior treatment 6.2. Patients must have recovery of hematological toxicity following previous therapy 6.3. Adequate recovery from major surgery prior to receiving study treatment
  7. Diagnostic imaging 7.1. Uptake in the primary tumor or metastatic tumour deposits on 68Ga-DOTATATE PET/CT at least higher than the liver uptake and performed within two months prior to registration 7.2. 123I-mIBG scintigraphy to be performed within two months prior to registration 7.3. CT or MRI of the primary tumor and bulky metastatic sites within two months prior to registration
  8. Laboratory requirements to be performed within 7 days prior to commencing trial treatment 8.1. Hematology: 8.1.1. Hemoglobin, If Hb is <120 g/L then patient will receive a blood transfusion prior to commencing trial treatment 8.1.2. Absolute neutrophil count > 1.0 x 109/L 8.1.3. Absolute Platelets > 50 x 109/L 8.2. Biochemistry: 8.2.1. Bilirubin within 1.5 x ULN 8.2.2. ALT within 2.5 x ULN 8.2.3. AST within 2.5 x ULN 8.2.4. GGT within 5 x ULN 8.2.5. ALP within 5 x ULN 8.2.6. Glomerular filtration rate >50mL/min/1.73m2 assessed by a recognised method, such as inulin, 51Cr-EDTA, 99mTc-DTPA or iohexol clearance and performed within 2 months prior to registration 8.2.7. Urinary catecholamine metabolites measured within 2 months prior to registration
  9. Peripheral blood stem cells (PBSC) 9.1. A minimum of 2 x106 CD34+ cells/kg (optimally 6 x106 CD34+ cells/kg) must be available for each study subject prior to registration
  10. Written informed consent from patient and/or parent(s) or legal guardian(s) in accordance with national regulations, prior to registration or any trial-related screening procedures

Exclusion Criteria:

  1. Not fit enough to undergo proposed study treatment, as assessed by national PI, considering precautions defined in the latest version of the 177Lutetium-DOTATATE SmPC.
  2. Pregnant or lactating patient
  3. Concurrent treatment with any anti-tumor agents
  4. Prior treatment with other radiolabeled somatostatin analogues
  5. Hypersensitivity to any component of the investigational drug 177Lutetium-DOTATATE
  6. Treatment with long-acting somatostatin analogues within 30 days, or with short-acting somatostatin analogues within 24 hours prior the administration of 177Lutetium-DOTATATE
  7. Hydronephrosis in either kidney on baseline MRI or CT; patients can still be eligible for inclusion if urinary tract obstruction can be ruled out by renography

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 177Lu-DOTATATE

A total of two doses of 177Lu-DOTATATE will be administered intravenously. The minimum time between treatments is 2 weeks.

A total of two doses of 177Lu-DOTATATE will be administered intravenously. A weight-based activity of 400 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT/CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, to avoid renal toxicity. The aim is to deliver two doses of 177Lu-DOTATATE two weeks apart. The minimum time between treatments is 2 weeks. The maximum time between treatments is 4 weeks.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Response by the Revised International Neuroblastoma Response Criteria (INRC) at 1 month after the completion of therapy
기간: 1 months following end of treatment

Treatment response assessed in accordance with the Revised International Neuroblastoma Response Criteria (INRC)

1 months following end of treatment

2차 결과 측정

결과 측정
측정값 설명
기간
Response based on 68Ga-DOTATOC PET/CT imaging at 1 and 4 months after completion of therapy in measurable target lesions
기간: 1 and 4 months following end of treatment

Response based on 68Ga-DOTATOC PET/CT imaging after completion of therapy in measurable target lesions

1 and 4 months following end of treatment
Response based on 123I-mIBG SPECT/CT imaging (when available) at 1 and 4 months after completion of therapy in measurable target lesions
기간: 1 and 4 months following end of treatment

Response based on 123I-mIBG SPECT/CT imaging (when available) after completion of therapy in measurable target lesions

1 and 4 months following end of treatment
Response by the Revised INRC criteria at 4 months after the completion of therapy
기간: 4 months following end of treatment

Response by the Revised INRC criteria

4 months following end of treatment
Progression-free survival
기간: Time from registration to progression or death, up to 5 years following end of treatment

Time to progress or death, whichever occurs first

Time from registration to progression or death, up to 5 years following end of treatment
Overall survival - up to 5 years after End of Treatment
기간: Time from registration to the the date of death, up to 5 years following end of treatment

Overall survival

Time from registration to the the date of death, up to 5 years following end of treatment
Hematological and renal toxicity according to CTCAE 5.0
기간: From first treatment dose until the date of first documented progression, assessed up to 60 months

Hematological and renal toxicity according to CTCAE 5.0

From first treatment dose until the date of first documented progression, assessed up to 60 months

기타 결과 측정

결과 측정
측정값 설명
기간
Dosimetry (absorbed dose in Gy) in measurable target lesions and risk organs
기간: At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)

Measured by SPECT/CT

At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)
Semi-quantitative analysis of the expression of SSTR-2 on immunohistochemistry in the primary tumor histology
기간: Throughout the trial treatment phase (5 years)

Semi-quantitative analysis of the expression of SSTR-2 on immunohistochemistry in the primary tumor histology

Throughout the trial treatment phase (5 years)
The uptake on 68Gallium-DOTATOC PET/CT by SUVmax (maximum standardized uptake value) in measurable target lesions
기간: At end of treatment, and 1 and 4 months after end of treatment.

Measured by SUVmax (maximum standardized uptake value)

At end of treatment, and 1 and 4 months after end of treatment.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 의자: Jakob Stenman, MD PhD, Karolinska University Hospital

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 5월 19일

기본 완료 (추정된)

2032년 12월 31일

연구 완료 (추정된)

2032년 12월 31일

연구 등록 날짜

최초 제출

2021년 5월 21일

QC 기준을 충족하는 최초 제출

2021년 5월 25일

처음 게시됨 (실제)

2021년 5월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 3일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • LuDO-N

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .